Mechanisms of Coronary Arteriolar Dysfunction in Type 2 Diabetes

2 型糖尿病冠状动脉功能障碍的机制

基本信息

  • 批准号:
    8383472
  • 负责人:
  • 金额:
    $ 34.52万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2010
  • 资助国家:
    美国
  • 起止时间:
    2010-02-01 至 2015-01-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Coronary arteriolar function is highly dependent on the integrity of endothelial cells (EC) and vascular smooth muscle cells (VSMC). Type 2 diabetes is associated with increased prevalence of ischemic heart disease, generally related to coronary artery disease that is associated with increased morbidity and death in diabetic patients. Epidermal growth factor receptor (EGFR) tyrosine kinase, of the many factors involved in cell growth and migration has been shown to be critical in the development of microvascular myogenic tone expressed as microvascular constriction in response to pressure increases. Our studies show an exacerbation of EGFR tyrosine kinase phosphorylation in coronary arteriolar from type 2 diabetic mice (db-/db- mice lacking leptin receptor gene) associated with coronary arteriolar dysfunction characterized by a reduced endothelial-dependent relaxation and potentiation of myogenic tone. Interestingly, in vivo inhibition of EGFR tyrosine kinase in db-/db- mice significantly improves coronary arteriolar function. Thus, enhanced EGFR tyrosine kinase in diabetes could be a critical up stream signal leading to a myriad of downstream signaling including oxidative stress, NFkB and PARP-1. More importantly, oxidative stress, nuclear factor kappa Beta (NFkB-transcriptional and nuclear factor) and poly(ADP-ribose)polymerase (PARP-1 nuclear factor), which are highly implicated in the etiology and progression of type 2 diabetes, could be critical in coronary arteriolar dysfunction in diabetes. Our preliminary data indicate an increase in oxidative stress (superoxide; O2.-), p65- NFkB activity and PARP-1 activity in coronary arterioles from db-/db- mice. Despite these connections, there has been no link determined between the coronary arteriolar pathology of diabetes with EGFR tyrosine kinase, oxidative stress, NFkB and PARP-1 pathway. Therefore, our central hypothesis is that exacerbation of EGFR tyrosine kinase phosphorylation leads to the increased ROS, NFkB and PARP activity, which in turn are responsible for coronary arteriolar dysfunction in type 2 diabetes. We will determine that: Aim 1. EGFR tyrosine kinase inhibition reduces O2.-, p65-NFkB and PARP activity, and improves coronary arteriolar function in db-/db- mice; Aim 2. Inhibition of O2.- production or scavenging of O2.- in db-/db- mice improves coronary arteriolar EC and VSMC dysfunction; Aim 3. Increased p65-NFkB and PARP-1 activities are critical in coronary arteriolar dysfunction in db-/db- mice. The successful completion of this project will determine the mechanisms how exacerbation of EGFR tyrosine kinase leads to the increased oxidative stress, NFkB and PARP-1 activity, which in turn are responsible for coronary arteriolar dysfunction, and will provide new insight into the vasculopathy mechanisms in diabetes.
描述(由申请方提供):冠状动脉功能高度依赖于内皮细胞(EC)和血管平滑肌细胞(VSMC)的完整性。2型糖尿病与缺血性心脏病的患病率增加相关,缺血性心脏病通常与冠状动脉疾病相关,冠状动脉疾病与糖尿病患者的发病率和死亡率增加相关。表皮生长因子受体(EGFR)酪氨酸激酶是参与细胞生长和迁移的许多因子中的一种,已被证明在微血管肌源性张力的发展中至关重要,所述张力表达为响应于压力增加的微血管收缩。我们的研究显示,2型糖尿病小鼠(缺乏瘦素受体基因的db-/db-小鼠)冠状动脉中EGFR酪氨酸激酶磷酸化的恶化与冠状动脉功能障碍相关,其特征在于内皮依赖性舒张减少和肌源性张力增强。有趣的是,在db-/db-小鼠体内抑制EGFR酪氨酸激酶显著改善冠状动脉功能。因此,糖尿病中增强的EGFR酪氨酸激酶可能是导致包括氧化应激、NFkB和PARP-1在内的无数下游信号传导的关键上游信号。更重要的是,氧化应激、核因子κ B(NF κ B-转录和核因子)和聚(ADP-核糖)聚合酶(PARP-1核因子)与2型糖尿病的病因学和进展密切相关,在糖尿病冠状动脉功能障碍中可能至关重要。我们的初步数据表明氧化应激(超氧化物; O2. -)增加,db-/db-小鼠冠状小动脉中的p65-NFkB活性和PARP-1活性。尽管存在这些联系,但尚未确定糖尿病冠状动脉病理学与EGFR酪氨酸激酶、氧化应激、NF κ B和PARP-1通路之间的联系。因此,我们的中心假设是EGFR酪氨酸激酶磷酸化的恶化导致ROS、NFkB和PARP活性增加,这反过来又是2型糖尿病冠状动脉功能障碍的原因。我们将确定:目标1。EGFR酪氨酸激酶抑制降低O2-,p65-NFkB和PARP活性,并改善db-/db-小鼠的冠状动脉功能;目的2.抑制O2。产生或清除O2。在db-/db-小鼠中改善冠状小动脉EC和VSMC功能障碍;目的3.增加的p65-NFkB和PARP-1活性在db-/db-小鼠的冠状动脉功能障碍中是关键的。该项目的成功完成将确定EGFR酪氨酸激酶的恶化如何导致氧化应激、NFkB和PARP-1活性增加的机制,这反过来又是导致冠状动脉功能障碍的原因,并将为糖尿病血管病变机制提供新的见解。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

KHALID MATROUGUI其他文献

KHALID MATROUGUI的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('KHALID MATROUGUI', 18)}}的其他基金

Interleukin 12 disruption provides beta cell and microvessel protection in type 2diabetes
白介素 12 破坏为 2 型糖尿病提供 β 细胞和微血管保护
  • 批准号:
    10219830
  • 财政年份:
    2020
  • 资助金额:
    $ 34.52万
  • 项目类别:
Stromal interaction molecule 1, immune cells, and vascular pathology in established hypertension
既定高血压中的基质相互作用分子 1、免疫细胞和血管病理学
  • 批准号:
    10673211
  • 财政年份:
    2020
  • 资助金额:
    $ 34.52万
  • 项目类别:
Stromal interaction molecule 1, immune cells, and vascular pathology in established hypertension
既定高血压中的基质相互作用分子 1、免疫细胞和血管病理学
  • 批准号:
    10206263
  • 财政年份:
    2020
  • 资助金额:
    $ 34.52万
  • 项目类别:
Stromal interaction molecule 1, immune cells, and vascular pathology in established hypertension
既定高血压中的基质相互作用分子 1、免疫细胞和血管病理学
  • 批准号:
    10455479
  • 财政年份:
    2020
  • 资助金额:
    $ 34.52万
  • 项目类别:
Interleukin 12 disruption provides beta cell and microvessel protection in type 2diabetes
白介素 12 破坏为 2 型糖尿病提供 β 细胞和微血管保护
  • 批准号:
    10650143
  • 财政年份:
    2020
  • 资助金额:
    $ 34.52万
  • 项目类别:
Interleukin 12 disruption provides beta cell and microvessel protection in type 2diabetes
白介素 12 破坏为 2 型糖尿病提供 β 细胞和微血管保护
  • 批准号:
    10444975
  • 财政年份:
    2020
  • 资助金额:
    $ 34.52万
  • 项目类别:
Mechanisms of Coronary Arteriolar Dysfunction in Type 2 Diabetes
2 型糖尿病冠状动脉功能障碍的机制
  • 批准号:
    7792312
  • 财政年份:
    2010
  • 资助金额:
    $ 34.52万
  • 项目类别:
Mechanisms of Coronary Arteriolar Dysfunction in Type 2 Diabetes
2 型糖尿病冠状动脉功能障碍的机制
  • 批准号:
    8013945
  • 财政年份:
    2010
  • 资助金额:
    $ 34.52万
  • 项目类别:
Mechanisms of Coronary Arteriolar Dysfunction in Type 2 Diabetes
2 型糖尿病冠状动脉功能障碍的机制
  • 批准号:
    8611809
  • 财政年份:
    2010
  • 资助金额:
    $ 34.52万
  • 项目类别:
MECHANISMS OF RESISTANCE ARTERY STRUCTURAL REMODELING IN HYPERTENSION
高血压中阻力动脉结构重塑的机制
  • 批准号:
    8167897
  • 财政年份:
    2010
  • 资助金额:
    $ 34.52万
  • 项目类别:

相似海外基金

cGAS-STING Pathway Targeting Replicative Adenoviruses with CD46 Tropism and AFP Promoter Conditional Replication Restriction for the Treatment of Hepatocellular Carcinoma
cGAS-STING 通路靶向具有 CD46 趋向性和 AFP 启动子的复制腺病毒条件性复制限制用于治疗肝细胞癌
  • 批准号:
    10436626
  • 财政年份:
    2021
  • 资助金额:
    $ 34.52万
  • 项目类别:
Glioma therapy with oncolytic adenoviruses and immunometabolic adjuvants
溶瘤腺病毒和免疫代谢佐剂治疗胶质瘤
  • 批准号:
    10557162
  • 财政年份:
    2021
  • 资助金额:
    $ 34.52万
  • 项目类别:
Molecular therapy of replication-competent adenoviruses targeting characteristic gene mutations found in mesothelioma
针对间皮瘤中发现的特征基因突变的具有复制能力的腺病毒的分子疗法
  • 批准号:
    21K08199
  • 财政年份:
    2021
  • 资助金额:
    $ 34.52万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Glioma therapy with oncolytic adenoviruses and immunometabolic adjuvants
溶瘤腺病毒和免疫代谢佐剂治疗胶质瘤
  • 批准号:
    10330464
  • 财政年份:
    2021
  • 资助金额:
    $ 34.52万
  • 项目类别:
Structural characterization of nucleoprotein cores of human adenoviruses
人腺病毒核蛋白核心的结构表征
  • 批准号:
    9807741
  • 财政年份:
    2019
  • 资助金额:
    $ 34.52万
  • 项目类别:
Molecular biology and pathogenesis of fowl adenoviruses
禽腺病毒的分子生物学和发病机制
  • 批准号:
    41625-2013
  • 财政年份:
    2018
  • 资助金额:
    $ 34.52万
  • 项目类别:
    Discovery Grants Program - Individual
The therapeutic strategies with augmented replications of oncolytic adenoviruses for malignant mesothelioma
溶瘤腺病毒增强复制治疗恶性间皮瘤的治疗策略
  • 批准号:
    18K15937
  • 财政年份:
    2018
  • 资助金额:
    $ 34.52万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Molecular biology and pathogenesis of fowl adenoviruses
禽腺病毒的分子生物学和发病机制
  • 批准号:
    41625-2013
  • 财政年份:
    2017
  • 资助金额:
    $ 34.52万
  • 项目类别:
    Discovery Grants Program - Individual
Exploring the effects of nutrient deprivation on T cells and oncolytic adenoviruses, in order to create immune activators for tumour therapy
探索营养剥夺对 T 细胞和溶瘤腺病毒的影响,以创造用于肿瘤治疗的免疫激活剂
  • 批准号:
    1813152
  • 财政年份:
    2016
  • 资助金额:
    $ 34.52万
  • 项目类别:
    Studentship
Research on detection of novel adenoviruses by genetic methods
新型腺病毒的基因检测研究
  • 批准号:
    16K09118
  • 财政年份:
    2016
  • 资助金额:
    $ 34.52万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了